Abstract: Objective To investigate the effect of Targeted therapy of epidermal growth factor Receptor tyrosine kinase inhibitor (EGFR-TKI) combined with TC chemotherapy on liver and kidney function in patients with Mutant non-small cell lung cancer. Methods A total of 100 patients with mutant non-small cell lung cancer admitted to Fuping County Hospital from June 2017 to June 2019 were selected as the study subjects for retrospective analysis. According to the treatment methods, the patients were divided into an observation group and a control group, with 50 cases in each group. The patients in the control group were treated with a single TC chemotherapy scheme, and the patients in the observation group were treated with EGFR-TKI Targeted therapy combined with TC chemotherapy scheme. The clinical efficacy, survival and changes of liver and kidney function indexes before and after treatment of the patients in the two groups were compared. Results The Objective remission rate and disease control rate of the observation group were significantly higher than those of the control group (P<0.05); The median PFS of the observation group was 11.26 (2.38-24.13), the median progression-free survival (PFS) of the control group was 9.25 (2.24-17.22), which was higher in the observation group than in the control group (χ²=4.536, P=0.041), and the median overall survival (OS) of the observation group was 21.23 (4.84-62.73). The median OS of the control group was 16.52 (5.27-50.27), which was higher in the observation group than in the control group (χ²=5.262, P=0.022); Before treatment, the levels of alt, AST, SCR and BUN in the two groups had no significant difference (P>0.05). After treatment, the levels of alt, AST, SCR and BUN in the two groups increased, but there was no significant difference between the observation group and the control group (P>0.05).Conclusion EGFR-TKI Targeted therapy combined with TC chemotherapy regimen has a significant effect in the treatment of mutant non-small cell lung cancer, and can improve the progression free survival period and total survival period of patients, and does not increase the degree of liver and kidney function damage compared with the single TC chemotherapy regimen.

Key words: skin growth factor receptor tyrosine kinase inhibitor, chemotherapy, mutant, non small cell lung cancer, liver function, renal function